Summary:

- The article discusses a novel gene therapy approach using CRISPR-Cas9 to treat Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration.
- The researchers developed a dual-vector CRISPR system that can efficiently correct the genetic mutation responsible for DMD in mouse models, leading to improved muscle function and extended lifespan.
- The findings suggest this gene therapy strategy holds promise for the treatment of DMD and potentially other genetic disorders, paving the way for future clinical trials and advancements in the field of molecular therapy.